Aspirin therapy in diabetes

Diabetes Care

Volumn 20, Issue 11, 1997, Pages 1767-1771

  Colwell, John A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR; SULFINPYRAZONE; TICLOPIDINE;

BLEEDING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; MULTICENTER STUDY; REVIEW; RISK MANAGEMENT;

EID: 0030784473     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.11.1767     Document Type: Review

References (31)

1. Stamler J, Vaccaro O, NeatonJD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434-444, 1993
2. Col well JA, Jokl R: Vascular thrombosis in diabetes. In Diabetes Melittas: Theory and Practice. 5th ed. Porte D, Sherwin R, Rifkin H, Eds. Norwalk, CT, Appleton and Lange, 1996, p. 207-216
3. Sagel J, Cohvell JA, Crook L, Laimins M: Increased platelet aggregation in early diabetes mellitus. Ann Intern Med 82: 733-738, 1975
4. Halushka Py Rogers RC, Loadholdt CB, Cohvell JA: Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med 97: 87-96, 1981
5. Davi G, Catalano I, Averna M: Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322: 1769-1774, 1990
6. Antiplatelet Trialists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: 71-72, 81-106, 1994
7. ETDRS Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 268: 1292-1300, 1992
8. Steering Committee of the Physicians' Health Study Research Group: Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321: 129-135, 1989
9. Patrono C, Davi G: Antiplatelet agents in the prevention of diabetic vascular complications. Diabetes Metab Rev 9: 1-13, 1993
10. Patrono C: Aspirin as an antiplatelet drug. N EnglJ Med 330: 1287-1294, 1994
11. DeMinno G, Silver MJ, Cerbone AM, Murphy S: Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 68: 886-891, 1986
12. Bell DSH: Stroke in the diabetic patient. Diabetes Care 17: 213-219, 1994
13. Clark RJ, Mayo G, Price P, Fitzgerald GA: Suppression of thromboxane A2 but not of systemic protacyclin by controlled-release aspirin. N Engl J Med 325: 1137-1141, 1991
14. 1S1S-2: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: 1S1S-2. Lancet ii: 349-360, 1988
15. Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH: A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 266: 521-527, 1991
16. The TIMAD Study Group: Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Opthalmol 108: 1577-1583, 1990
17. Ceriello A, Motz E: Prevention of vascular events in diabetes mellitus: which "anti thrombotic" therapy? Diabetologa 39: 1405-1406, 1996
18. Yudkin JS: Which diabetic patients should be taking aspirin? BMJ 311: 641-642, 1995
19. Yudkin J: Assessing the evidence on aspirin in diabetes mellitus, Gemini or Libra; lumping or splitting; surrogate or hard; low or high; interventionalist or nihilist. Diabetologia 39: 1407-1408, 1996
20. KHmt CR, Knatterud CL, Meinen CL, Prout TE: Study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. I. Design, methods, and baseline results. Diabetes 19: 747-783, 1970
21. UKPDS Group: UK Prospective Diabetes Study 6: complications in newly diagnosed type II diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 13: 1-11, 1990
22. Uusitupa MIJ, Niskanen LK, Siitonen O, Voutilainea E, Pyörälä R: Ten-year cardiovascular mortality in relation to risk factors and abnormalities of lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologa 36: 1175-1184, 1993
23. McGill HC Jr, McMahan A, Malcolm GT, Oalmann MD, StrongJP, the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group: Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Arteriol Throm Vase Bio 15: 431-440, 1995
24. Haffner SM, Stem MP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263: 2893-2898, 1990
25. Gall MA, Borch-Johnson K, Hougaard P, Nielson FS, Parving H: Albuminuria and poor glycémie control predict mortality in NIDDM. Diabetes 44: 1303-1309, 1995
26. Mogensen CE, Keane WE; Bennett PH, Jerums G, Parving H, Passa P, Steffes MW, Striker GE, Viberti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346: 1080-1084, 1995
27. Mykkanen L, Haffrier SM, KuuistoJ, Pyöräla K, Laakso M: Microalbuminuria precedes the development of NIDDM. Diabetes 43: 552-557, 1994
28. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet ii: 3-9, 1987
29. Juhan-Vague I, Alessi MC, Vague P: Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherosclerosis. Diabetolopa 34: 457-462, 1991
30. Ernst E, Resch K: Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118: 956-963, 1993
31. Abraira C, ColwellJ, Nuttall F, Sawin CT, Henderson W, ComstockJP, Emanuele N, Levin SR, Pacold I, Lee HS, the Veterans Affairs Cooperative Study on Glycémie Control and Complications in Type II Diabetes Group: Cardiovascular events and correlates in the VA Feasibility Trial. Arch Int Med 157: 181-188, 1997